<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02930941</url>
  </required_header>
  <id_info>
    <org_study_id>844609</org_study_id>
    <nct_id>NCT02930941</nct_id>
  </id_info>
  <brief_title>Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department</brief_title>
  <official_title>Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is estimated that epistaxis results in 4.5 million emergency department visits per year
      throughout the United States. Due to the adverse effects of standard treatment options for
      epistaxis, tranexamic acid (TXA) may be considered an attractive option. In previous studies,
      when used with nasal packing, TXA showed faster time to control of bleeding. The goal of this
      study is to determine the efficacy and safety of topical intranasal TXA applied via atomizer
      for patients with epistaxis who present to the emergency department.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, single-center, double-blinded, placebo controlled study
      comparing efficacy and safety of topical intranasal tranexamic acid for epistaxis. The
      primary outcome was time to control of bleeding and secondary outcomes were length of stay in
      the emergency department, re-bleeding within the first 24 hours, and re-bleeding at one week.
      Safety outcomes were the incidence of thromboembolic events and other drug-related adverse
      events.

      Patients aged 18 years of age or older and diagnosed with anterior epistaxis were included.
      Patients were excluded if they were unable to consent, do not have a valid telephone number,
      pregnant women, prisoners, cognitively impaired individuals, diagnosis of posterior
      epistaxis, major trauma, bleeding disorder (such as thrombocytopenia or hemophilia),
      hemodynamically unstable, or had a known hypersensitivity to study medication.

      Patients were randomly assigned to tranexamic acid treatment group or placebo group. After
      consenting, patients received TXA (100 mg/1mL) or 0.9% sodium chloride (1 mL) in to the
      affected nostril(s) via intranasal atomization device. If bleeding did not cease, two repeat
      doses were allowed and after twenty minutes of continued bleeding the study physician could
      treat with any additional treatment options. Patients were contacted via telephone within one
      week to inquire about incidences of re-bleeding or any complications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to control of bleeding</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the Emergency Department</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-bleeding within the first 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-bleeding within the first week</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thromboembolic events</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug-related events</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Epistaxis</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid (100 mg/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TXA (100 mg/1mL) sprayed in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% Sodium Chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>TXA (100 mg/1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).</description>
    <arm_group_label>Tranexamic Acid (100 mg/mL)</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Sodium Chloride</intervention_name>
    <description>0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).</description>
    <arm_group_label>0.9% Sodium Chloride</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with anterior epistaxis

        Exclusion Criteria:

          -  Unable to consent, do not have a valid telephone number, pregnant women, prisoners,
             cognitively impaired individuals, diagnosis of posterior epistaxis, major trauma,
             bleeding disorder (such as thrombocytopenia or hemophilia), hemodynamically unstable,
             or had a known hypersensitivity to study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimee Moulin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aimee Moulin, MD</last_name>
    <phone>916-703-6110</phone>
    <email>akmoulin@ucdavis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brian Dang, PharmD</last_name>
    <phone>714-823-5107</phone>
    <email>brian.dang@ucdenver.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Moulin, MD</last_name>
      <phone>916-703-6110</phone>
      <email>akmoulin@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christopher B Adams, PharmD</last_name>
      <phone>916-703-6110</phone>
      <email>chradams@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Aimee Moulin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Dang, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brittany Traylor, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher B Adams, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Verena Schandera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howard McKinney Jr, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Catlin Jr, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Morgan DJ, Kellerman R. Epistaxis: evaluation and treatment. Prim Care. 2014 Mar;41(1):63-73. doi: 10.1016/j.pop.2013.10.007. Review.</citation>
    <PMID>24439881</PMID>
  </reference>
  <reference>
    <citation>Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32. Review.</citation>
    <PMID>10400410</PMID>
  </reference>
  <reference>
    <citation>Kucik CJ, Clenney T. Management of epistaxis. Am Fam Physician. 2005 Jan 15;71(2):305-11. Review.</citation>
    <PMID>15686301</PMID>
  </reference>
  <reference>
    <citation>Singer AJ, Blanda M, Cronin K, LoGiudice-Khwaja M, Gulla J, Bradshaw J, Katz A. Comparison of nasal tampons for the treatment of epistaxis in the emergency department: a randomized controlled trial. Ann Emerg Med. 2005 Feb;45(2):134-9.</citation>
    <PMID>15671968</PMID>
  </reference>
  <reference>
    <citation>Wolfe TR, Braude DA. Intranasal medication delivery for children: a brief review and update. Pediatrics. 2010 Sep;126(3):532-7. doi: 10.1542/peds.2010-0616. Epub 2010 Aug 9. Review.</citation>
    <PMID>20696726</PMID>
  </reference>
  <results_reference>
    <citation>Pallin DJ, Chng YM, McKay MP, Emond JA, Pelletier AJ, Camargo CA Jr. Epidemiology of epistaxis in US emergency departments, 1992 to 2001. Ann Emerg Med. 2005 Jul;46(1):77-81.</citation>
    <PMID>15988431</PMID>
  </results_reference>
  <results_reference>
    <citation>Villwock JA, Jones K. Recent trends in epistaxis management in the United States: 2008-2010. JAMA Otolaryngol Head Neck Surg. 2013 Dec;139(12):1279-84. doi: 10.1001/jamaoto.2013.5220. Review.</citation>
    <PMID>24136624</PMID>
  </results_reference>
  <results_reference>
    <citation>White A, O'Reilly BF. Oral tranexamic acid in the management of epistaxis. Clin Otolaryngol Allied Sci. 1988 Feb;13(1):11-6.</citation>
    <PMID>3286068</PMID>
  </results_reference>
  <results_reference>
    <citation>Tibbelin A, Aust R, Bende M, Holgersson M, Petruson B, Rundcrantz H, Alander U. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL J Otorhinolaryngol Relat Spec. 1995 Jul-Aug;57(4):207-9.</citation>
    <PMID>7478455</PMID>
  </results_reference>
  <results_reference>
    <citation>Zahed R, Moharamzadeh P, Alizadeharasi S, Ghasemi A, Saeedi M. A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. Am J Emerg Med. 2013 Sep;31(9):1389-92. doi: 10.1016/j.ajem.2013.06.043. Epub 2013 Jul 30.</citation>
    <PMID>23911102</PMID>
  </results_reference>
  <results_reference>
    <citation>Utkewicz MD, Brunetti L, Awad NI. Epistaxis complicated by rivaroxaban managed with topical tranexamic acid. Am J Emerg Med. 2015 Sep;33(9):1329.e5-7. doi: 10.1016/j.ajem.2015.02.049. Epub 2015 Mar 6.</citation>
    <PMID>25895714</PMID>
  </results_reference>
  <results_reference>
    <citation>Klepfish A, Berrebi A, Schattner A. Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med. 2001 Mar 12;161(5):767.</citation>
    <PMID>11231712</PMID>
  </results_reference>
  <results_reference>
    <citation>Aguilera X, Martínez-Zapata MJ, Hinarejos P, Jordán M, Leal J, González JC, Monllau JC, Celaya F, Rodríguez-Arias A, Fernández JA, Pelfort X, Puig-Verdie Ll. Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trial. Arch Orthop Trauma Surg. 2015 Jul;135(7):1017-25. doi: 10.1007/s00402-015-2232-8. Epub 2015 May 7.</citation>
    <PMID>25944156</PMID>
  </results_reference>
  <results_reference>
    <citation>Waldow T, Szlapka M, Haferkorn M, Bürger L, Plötze K, Matschke K. Prospective clinical trial on dosage optimizing of tranexamic acid in non-emergency cardiac surgery procedures. Clin Hemorheol Microcirc. 2013 Jan 1;55(4):457-68. doi: 10.3233/CH-131782.</citation>
    <PMID>24113504</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>epistaxis</keyword>
  <keyword>emergency medicine</keyword>
  <keyword>intranasal</keyword>
  <keyword>TXA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Epistaxis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

